TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15113639
Drug: Cost-sharing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-sharing group (essential drugs)
Study: 15113639
Drug: Cost-sharing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-sharing group (non-essential drugs)
Study: 15113639
Drug: Non cost-sharing
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non cost-sharing group (essential drugs)
Study: 15113639
Drug: Non cost-sharing
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non cost-sharing group (non-essential drugs)
Study: 15113639
Drug: Prescriptions above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions above the upper bound of the cost-sharing schedule
Study: 7706571
Drug: AT III
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT III concentrates administered at an initial dose of 60 U/kg followed by 10 U/kg every six hours
Study: 7706571
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with AT III)
Study: 3123116
Drug: Combined glyburide-insulin
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined glyburide-insulin therapy
Study: 29380128
Drug: Fexapotide triflutate
Normalized name: Corticorelin Ovine Triflutate
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexapotide triflutate 2.5 mg transrectal injectable (FT)
Study: 27272079
Drug: Clindamycin‐BP 3.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin‐BP 3.75% gel
Study: 27272079
Drug: Adapalene 0.3%‐BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.3%‐BP 2.5% gel
Study: 20839440
Drug: TCM-WM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM-WM treatment group
Study: 18031547
Drug: High trough
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High trough plasma VPA concentrations (above 100 microg/ml for women, above 130 microg/ml for men)
Study: 16159735
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with PDT using topical methyl aminolevulinate (MAL)
Study: 16159735
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments of MAL-PDT 1 week apart
Study: 11286374
Drug: Medical Resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Resonance Therapy Music (MRT‐Music)
Study: 1438624
Drug: dl-fenfluramine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-fenfluramine (1.0 mg/kg)
Study: 3895409
Drug: Topical streptokinase‐streptodornase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical streptokinase‐streptodornase (Varidase) solution
Study: 30145927
Drug: Percutaneous mitral-valve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous mitral-valve repair in addition to medical therapy
Study: 26809253
Drug: Insulin Detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin Detemir (second period)
Study: 26809253
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (switched to Insulin Detemir)
Study: 24684165
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% plus sunscreen pre-treatment for 2 weeks.
Study: 24147129
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (sham analgesic cream)
Study: 18339032
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E and selenium supplementation (Vitamin E: 140 mg alpha‐tocopherol and selenium: 200 microg)
Study: 14623531
Drug: Letrozole (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (aromatase inhibitor) with testosterone
Study: 10873072
Drug: Anastrozole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (both doses combined)
Study: 1424202
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (40 mg daily for 3 months)
Study: 2412054
Drug: Specific serotonergic
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific serotonergic antagonists (oral or intravenous)
Study: 27817128
Drug: L-arginine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine with vitamins B6, folic acid and B12 (Telcor® Arginin plus)
Study: 24752034
Drug: Motive-oriented therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motive-oriented therapeutic relationship (MOTR) added to general psychiatric management (GPM) treatment
Study: 24752034
Drug: General psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: General psychiatric management (GPM) treatment
Study: 22759549
Drug: 2% Chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Chlorhexidine gluconate (CHG) applied thrice-weekly
Study: 20454851
Drug: IgPro20 (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 (20% liquid SCIG) administered weekly
Study: 12030952
Drug: Oral beclometasone
Normalized name: beclomethasone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclometasone dipropionate (BDP) 5 mg/day plus 5‐ASA 3.2 g/day
Study: 12030952
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 5‐ASA 3.2 g/day
Study: 18382886
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor therapy
Study: 7552537
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg x 2 p.o.
Study: 7552537
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime 1.5 g x 3 i.v. on the day of surgery
Study: 1310566
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of WSDF/day consisting of psyllium husk, pectin, and guar and locust bean gums for 4 weeks
Study: 1310566
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of WSDF/day from high-viscosity guar gum for 4 weeks
Study: 1310566
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of WSDF/day
Study: 1310566
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of WSDF/day
Study: 17105779
Drug: Eligibility criteria
Normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligibility criteria for major asthma RCTs (on treatment)
Study: 16366758
Drug: venlafaxine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine (150 to 225 mg daily, titrated based on symptoms) + behavioral counseling + transdermal nicotine replacement therapy (22 mg/day)
Study: 16366758
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + behavioral counseling + transdermal nicotine replacement therapy (22 mg/day)
Study: 7546831
Drug: Serotonin antagonists
Normalized name: Serotonin antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin antagonists (ondansetron, granisetron, tropisetron)
Study: 7546831
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of steroids and dopamine D2 antagonist metopimazine
Study: 7011085
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg of hydrallazine
Study: 28283340
Drug: IV push
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV push low dose ketamine (0.3 mg/kg)
Study: 28283340
Drug: Short infusion
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short infusion low dose ketamine (0.3 mg/kg)
Study: 27009433
Drug: Geneva cocktail
Normalized name: amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Geneva cocktail (combination of low‐dose caffeine, flurbiprofen, omeprazole, dextromethorphan, midazolam, fexofenadine, bupropion)
Study: 27009433
Drug: CYP probes
Normalized name: estradiol cypionate / testosterone cypionate Injectable Solution [Duo-Cyp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP probes administered alone
Study: 25080037
Drug: Test implant
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implant (4.5-mm-diameter moderately roughened implant with a rounded 6-mm abutment)
Study: 25080037
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant (3.75-mm diameter as-machined implant with a conically shaped 5.5-mm abutment)
Study: 19309367
Drug: Long-pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-pulsed dye laser (LPDL) treatment (V‐beam Perfecta, 595 nm)
Study: 19309367
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) treatment (Ellipse Flex)
Study: 17311692
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel (200 mg/m2) and carboplatin (AUC 6) followed by observation
Study: 17311692
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with paclitaxel (200 mg/m2) and carboplatin (AUC 6) followed by radiation therapy (RT) at 5000 cGy in 25 fractions over 5 weeks
Study: 15206988
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg fosfluconazole once daily for 14 days
Study: 15206988
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg fluconazole once daily for 14 days
Study: 15206988
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg fosfluconazole once daily for 10 days (no loading dose)
Study: 15206988
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 1000 mg on day 1 followed by 500 mg for 9 days (one loading dose)
Study: 15206988
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of 1000 mg on days 1 and 2 followed by 500 mg for 8 days (two loading doses)
Study: 28938877
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and insulin (n=10)
Study: 24733715
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy (NOT) at 3.0 l/min
Study: 24733715
Drug: No nocturnal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nocturnal oxygen therapy (no NOT)
Study: 21506190
Drug: Sage leaf
Normalized name: sage leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sage leaf extract (500 mg capsule every 8 hours for 2 months)
Study: 19565667
Drug: Caudal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.25% levobupivacaine (1 ml.kg(‐1)) alone
Study: 12622344
Drug: Lorazepam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.0 mg/70 kg orally administered)
Study: 12622344
Drug: Scopolamine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.6 mg/70 kg subcutaneously administered)
Study: 3751450
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (protocol B, without hemorheologic treatment)
Study: 29846091
Drug: Melatonin (MEL)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MEL) 10 mg
Study: 28059034
Drug: Midazolam 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2.5 mg and Haloperidol 2.5 mg (IM) plus Morphine 0.05 mg/kg (IV)
Study: 28059034
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water 5 cc (IM) plus Morphine 0.05 mg/kg (IV)
Study: 20660712
Drug: Potential markers
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential markers for cancer diagnosis, prognosis, or therapy monitoring
Study: 18339487
Drug: IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT with dose escalation
Study: 10488702
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion and vasoactive drugs followed by sclerotherapy
Study: 10488702
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy at diagnostic endoscopy
Study: 9601759
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mg/kg/day i.m. over 3 days)
Study: 6765526
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (recombinant DNA)
Study: 6765546
Drug: Purified porcine
Normalized name: Insulin purified porcine
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified porcine insulin (PPI)
Study: 30589984
Drug: Cytisine capsules
Normalized name: cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisine capsules (25-day supply)
Study: 30589984
Drug: Varenicline tablets
Normalized name: Varenicline Tablets
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline tablets (12-week supply)
Study: 18957828
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy (BNCT) followed by X-ray treatment (XRT) of 20 to 30 Gy
Study: 18957828
Drug: Boron neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron neutron capture therapy (BNCT) (protocol 1 and 2 together)
Study: 12381087
Drug: Continuous ATP
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ATP injection
Study: 7616871
Drug: Gynodian Depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynodian Depot cartridges (4 mg estradiovalerate and 200 mg prasteronenantate) given as muscular injection in 6-10 week intervals (mean 7 weeks +/- 4 days)
Study: 2654080
Drug: naftifin hydrochloride
Normalized name: Naftifine Hydrochloride
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naftifin hydrochloride cream
Study: 26486824
Drug: TAP‐144‐SR (6M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP‐144‐SR (6M) 22.5 mg
Study: 26486824
Drug: TAP‐144‐SR (3M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP‐144‐SR (3M) 11.25 mg
Study: 21574291
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy without acupuncture
Study: 18824862
Drug: Dexibuprofen 200
Normalized name: ibuprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 200 mg
Study: 18824862
Drug: Dexibuprofen 300
Normalized name: Dexibuprofen 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 300 mg
Study: 16710256
Drug: Eptifibatide (Integrilin)
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide (Integrilin) administered as two boluses of 180 mg/kg followed by infusion of 2 mg/kg per min for 24 hours and 1.3 mg/kg for 48 hours
Study: 16710256
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GP IIb-IIIa antagonists used)
Study: 15633811
Drug: Real intradermal
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real intradermal acupuncture on shen‐men (He‐7) and nei‐kuan (EH‐6) for 2 days
Study: 9431347
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy and monitoring by experienced physicians and surgeons for patients with fulminant colitis, toxic megacolon, or perforation.
Study: 7943771
Drug: Autologous +
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous + leukocyte‐depleted red blood cell transfusion (800 +/- 200 mL autologous blood and 2.2 +/- 2.0 units of SAGM red blood cells)
Study: 31504126
Drug: 10 years
Normalized name: Neocate Junior Powder Children 1-10 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 years of tamoxifen treatment
Study: 31504126
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of tamoxifen treatment
Study: 22137077
Drug: Initial medical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial medical therapy after publication of trial results
Study: 8976781
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone cream applied twice daily for 4 weeks
Study: 8976781
Drug: Neutral cream
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral cream (Vaseline) applied twice daily for 4 weeks
Study: 1353011
Drug: L-threonine (Thr)
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-threonine (Thr)
Study: 6396839
Drug: Cloxacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin (2 g intravenously 2 hours before operation, followed by 1 g every 6 hours for 2 days and 1 g orally for 8 more days postoperatively)
Study: 30052055
Drug: MG-NMES
Normalized name: MG 217 Psoriasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG-NMES
Study: 17845270
Drug: Tamoxifen (20-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20-140 mg/day)
Study: 11694609
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (10 mg/d)
Study: 11694609
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + Zinc supplementation (10 mg of each/d)
Study: 9212763
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg intravenously)
Study: 1454657
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 1.6 mg daily
Study: 1454657
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 10 mg daily
Study: 3306546
Drug: Twice-daily instillation
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily instillation for 1 week
Study: 26211765
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA in parenteral nutrition
Study: 26211765
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without omega-3 PUFA in parenteral nutrition)
Study: 23205864
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone tablets 200 mg vaginally daily (Group A)
Study: 23205864
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg progesterone intramuscular every third day (Group B)
Study: 23205864
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (Group B)
Study: 17080540
Drug: Xiong‐gui‐jiao‐ai‐tang (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiong‐gui‐jiao‐ai‐tang (7.5 g/day)
Study: 11053334
Drug: Theophylline (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (4.5 mg/kg)
Study: 10954004
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (nitrendipine or nifedipine)
Study: 10954004
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium antagonists
Study: 1553052
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate (orally administered)
Study: 27297634
Drug: Anxiolytic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytic or hypnotic drugs
Study: 23341518
Drug: Anthracycline-only chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline-only chemotherapy (doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin plus cyclophosphamide followed by CMF)
Study: 23341518
Drug: Chemotherapy combining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combining doxorubicin and docetaxel (doxorubicin plus docetaxel followed by CMF or doxorubicin followed by docetaxel followed by CMF)
Study: 23341518
Drug: Anthracycline-only chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline-only chemotherapy
Study: 20595800
Drug: Pegvisomant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (10 to 40 mg/day for 18 months)
Study: 8959150
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bactec and MB‐Check systems
Study: 1530193
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live attenuated influenza A (H3N2) virus vaccine
Study: 4064565
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution (saline: 154 mmol of NaCl/l) plus ascorbic acid, 1 mg/ml (control)
Study: 24604409
Drug: MAG gel
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG gel in sugar cookies (40 g)
Study: 24604409
Drug: MAG gel
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG gel in baked products (high and low moisture)
Study: 22801836
Drug: Peribulbar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injection of gadolinium and lidocaine hydrochloride, 2%, without epinephrine